Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00490022 · ClinicalTrials.gov registry record · Phase 1
Effect of Dihydrotestosterone (DHT) on Prostate Tissue [Short Title: DHT-3]
A Phase 1 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT00490022 is a Phase 1 study that has completed, run by University of Washington. The registered enrollment target is 31 participants.
The verdict
NCT00490022, a Phase 1 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this research study is to understand the effects of a male hormone normally made in the body called Dihydrotestosterone (DHT) on the prostate gland that is located under the bladder. The knowledge gained from this study may be used to help in the future to develop a safe male hormonal contraceptive to prevent pregnancy, in the safe treatment of low male hormone levels in men, and in the treatment and prevention of diseases of the prostate. The investigators will be giving DHT in a gel form, to be applied to the skin, or a placebo gel (with no active drug in it). The investigators want to see the effects of DHT on levels of hormones in the blood and in the prostate gland itself. In addition, the investigators will be studying the effects of DHT on the cells and genes expressed within the prostate. The effect of DHT on the prostate is not known. Some studies suggest blocking production of DHT in the prostate helps growth of the gland with aging (a condition known as benign prostatic hyperplasia, or BPH for short) and may prevent prostate cancer. On the other hand, DHT administration may shrink the prostate, suggesting it may be beneficial for some men. Therefore, further studies looking at the effect of DHT on the prostate are needed.
Interventions
- DRUG Placebo gel
- DRUG Dihydrotestosterone (DHT) gel (0.7%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00490022
The ClinicalTrials.gov registry entry for NCT00490022 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo gel is the first listed.
NCT00490022 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00490022 about?
NCT00490022 is a clinical study titled "Effect of Dihydrotestosterone (DHT) on Prostate Tissue [Short Title: DHT-3]". The purpose of this research study is to understand the effects of a male hormone normally made in the body called Dihydrotestosterone (DHT) on the prostate gland that is located under the bladder. The knowledge gained from this study may be used to help in the future to develop a safe male hormonal...
What is the current status of trial NCT00490022?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2007-06. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00490022?
The interventions under investigation include: Placebo gel (DRUG), Dihydrotestosterone (DHT) gel (0.7%) (DRUG).
Who is sponsoring clinical trial NCT00490022?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.